1. Home
  2. RIGL vs GROY Comparison

RIGL vs GROY Comparison

Compare RIGL & GROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • GROY
  • Stock Information
  • Founded
  • RIGL 1996
  • GROY 2020
  • Country
  • RIGL United States
  • GROY Canada
  • Employees
  • RIGL N/A
  • GROY N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • GROY
  • Sector
  • RIGL Health Care
  • GROY
  • Exchange
  • RIGL Nasdaq
  • GROY Nasdaq
  • Market Cap
  • RIGL 334.5M
  • GROY 269.3M
  • IPO Year
  • RIGL 2000
  • GROY 2021
  • Fundamental
  • Price
  • RIGL $18.28
  • GROY $1.47
  • Analyst Decision
  • RIGL Buy
  • GROY Strong Buy
  • Analyst Count
  • RIGL 5
  • GROY 4
  • Target Price
  • RIGL $36.40
  • GROY $3.31
  • AVG Volume (30 Days)
  • RIGL 205.1K
  • GROY 1.5M
  • Earning Date
  • RIGL 05-06-2025
  • GROY 05-07-2025
  • Dividend Yield
  • RIGL N/A
  • GROY N/A
  • EPS Growth
  • RIGL N/A
  • GROY N/A
  • EPS
  • RIGL 2.08
  • GROY N/A
  • Revenue
  • RIGL $203,077,000.00
  • GROY $10,347,000.00
  • Revenue This Year
  • RIGL $24.45
  • GROY $88.55
  • Revenue Next Year
  • RIGL $7.23
  • GROY $52.87
  • P/E Ratio
  • RIGL $8.77
  • GROY N/A
  • Revenue Growth
  • RIGL 70.16
  • GROY 99.94
  • 52 Week Low
  • RIGL $7.48
  • GROY $1.16
  • 52 Week High
  • RIGL $29.82
  • GROY $2.11
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 47.44
  • GROY 46.49
  • Support Level
  • RIGL $17.65
  • GROY $1.51
  • Resistance Level
  • RIGL $19.75
  • GROY $1.60
  • Average True Range (ATR)
  • RIGL 1.46
  • GROY 0.06
  • MACD
  • RIGL -0.02
  • GROY -0.00
  • Stochastic Oscillator
  • RIGL 16.39
  • GROY 21.58

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About GROY Gold Royalty Corp.

Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.

Share on Social Networks: